Peripheral Matters: FDA Approves Covered Stent for Treatment of Aortic Wall Injury

CardioSource WorldNews Interventions | The U.S. Food and Drug Administration (FDA) recently approved the NuMED Cheatham Platinum (CP) Stent System for the prevention and/or treatment of aortic wall injury (AWI) in patients with coarctation of the aorta involving a compliant aortic isthmus or first segment of the descending aorta where there is adequate size and patency of at least one femoral artery and balloon angioplasty is contraindicated or predicted to be ineffective.

Stent therapy for coarctation of the aorta offers a non-surgical alternative to traditional operative repair of the aortic obstruction with similar results and complication rates. Stent treatment also has a lower rate of recurrence and aortic wall injury compared to balloon dilation alone.

Covered stent therapy provides similar outcomes and allows for simultaneous treatment of aortic wall injuries, such as aneurysm and pseudo-aneurysm that might be present, related to previous surgical or catheter based therapy of the coarctation.

In the COAST II clinical trial, published in JACC: Cardiovascular Interventions, the average ascending-to-descending aorta systolic gradient improved from 27 ± 20 mm Hg to 4 ± 6 mm Hg. Complete coverage of pre-existing AWI was achieved in 66 of 71 patients (93%) with AWI who received the stent. No patients have required additional or subsequent surgical therapy. Approximately 15% of patients require further dilation of the stent after a few years, mostly to keep up with patient growth. Only two patients experienced clinically apparent access artery injury, requiring repair. Subclinical femoral artery injury was suspected in nine patients and borderline femoral artery injury occurred in ten additional patients.

“FDA approval of the NuMED CP and Covered CP stents marks important milestones in the catheter mediated therapy of children and adults with congenital heart disease,” states Richard E. Ringel, MD, FACC, a professor of pediatrics in the division of pediatric cardiology at Johns Hopkins School of Medicine. “These are the first large diameter, balloon expandable stents to be approved by the FDA for usage in the aorta. The Covered CP stent increases the safety of therapy for coarctation of the aorta.”

He adds that, “for years, coarctation of the aorta therapy has been conducted safely by catheter techniques in the catheterization laboratory. However, the risk of serious, life threatening complication has now been further reduced by giving physicians the ability to immediately repair an unexpected aortic tear. Furthermore, physicians can hopefully make aortic tears even rarer, by using the Covered CP stent prophylactically when treating coarctation of the aorta in high risk patients.”

A Closer Look at the COAST II Trial

The COAST II (Covered Cheatham-Platinum Stents for Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta Trial) is a multicenter, single-arm trial using the CCPS for the treatment and/or prevention of AWI in patients with CoA and pre-existing AWI or increased risk of AWI. Patients were enrolled if they had a history of CoA with pre-existing AWI (Treatment group) or with increased risk of AWI (Prevention group). Pre/post-implant hemodynamics and angiography were reported. A core lab performed a standardized review of all angiograms. One-month follow-up was reported.

A total of 158 patients (65% male; median age, 19 years) underwent placement of CCPS. Eighty-three patients had pre-existing AWI. The average ascending-to-descending aorta systolic gradient improved from 27 ± 20 mm Hg to 4 ± 6 mm Hg. Complete coverage of pre-existing AWI was achieved in 66/71 patients (93%) with AWI who received a single CCPS. Ultimately, complete coverage of AWI was achieved in 76/83 patients (92%); seven patients had minor endoleaks that did not require repeat intervention. Four patients experienced important access site vascular injury. There were no acute AWIs, repeat interventions, or deaths.

The authors concluded that CCPS can effectively treat and potentially prevent aortic wall injury associated with CoA.


  1. Taggart NW, Minahan M, Cabalka AK, et al. JACC Intv. 2016;9(5):484-93.
Read the full July/August issue of CardioSource WorldNews Interventions at

Clinical Topics: Congenital Heart Disease and Pediatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Vascular Medicine, Congenital Heart Disease, CHD & Pediatrics and Interventions, Interventions and Structural Heart Disease, Interventions and Vascular Medicine

Keywords: CardioSource WorldNews Interventions, Angioplasty, Balloon, Aorta, Aorta, Thoracic, Aortic Coarctation, Femoral Artery, Platinum, Stents, United States Food and Drug Administration, Vascular System Injuries

< Back to Listings